- R&D in PCSK9 monoclonal antibodies for prevention of cardiovascular diseases in high-risk patients strengthens revenue potential in cholesterol lowering drugs market
- Strategic agreements notably in Europe will help players bolster their cardiovascular portfolio; personalized approach to gain traction
ALBANY, New York, March 19, 2020 /PRNewswire/ -- Growing health burden of cardiovascular diseases worldwide particularly mortality coronary artery diseases stimulate drug makers to increase their stakes in cholesterol lowering drugs market. A new Transparency Market Research (TMR) study estimated the worth of the market to be ~US$ 29 bn in 2018.
Growing number of new drugs, particularly PCSK9 inhibitors and nicotinic acid, has helped the global healthcare industry target patients who are high risk of cardiovascular events such as hypercholesterolemia. In coming years, clinical trials involving PCSK9 inhibitors will invigorate the drug pipelines. All these will propel the market clock a CAGR of ~3% during 2019–2027.
Analysts at TMR opine that though statins witness wide acceptance in patients for lowering cholesterol, given the side effects healthcare companies need to move cautiously. Hence, players are stressing on the high safety profile of statins combined with Ezetimibe or PCSK9 inhibitors to reduce LDL-C, and to boost drug tolerance in patients.
Key Takeaways in Cholesterol Lowering Drugs Market Study
Of all drug classes, statins and combination segment held the major share in 2018; the segment expected to continue retain its lead through 2027
Among the key drug classes, PCSK9 inhibitors to grow at promising rate year-over-year from 2019 to 2027; new approvals key to growth
Of the various indications, hypercholesterolemia was the leasing segment in 2018; however, coronary artery diseases expected to attract more investments among drug makers
Among the various distribution channels, retail pharmacies accounted for the major revenue in 2018; patients' preference attribute the segmental growth
Regionally, North America led the market in 2018; it is likely to contribute the dominant share, attributed mainly to rising prescription of cholesterol lowering drugs
Asia Pacific to witness a remarkably high growth during 2019 – 2027; large patient pool key to its evolution
Explore 196 pages of top-notch research, incisive insights, and detailed country-level projections. Gain business intelligence on Cholesterol Lowering Drugs Market (Drug Class: Statins & Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors, and Others; Indication: Hypercholesterolemia, Coronary Artery Disease, and Higher Triglycerides; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 – 2027. https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28142
Cholesterol Lowering Drugs Market: Key Driving Factors and Avenues
The high risk of heart diseases is evident in the marked prevalence of cardiovascular diseases (CVD), which is a key driver for development of cholesterol lowering drugs pipeline. Some of the statistics that help the epidemiology of CVD are:
Per an estimation by the WHO, CVD is leading cause of death globally with an estimated 17.7 million deaths in 2015.
1 in every 4 deaths is caused by CVD in the U.S.
The markedly high prevalence of coronary artery diseases is one of the foremost drivers of the cholesterol lowering drugs market
According to CDC, 18.2 million adults with age 20 years or more have coronary artery diseases; the prevalence of the disease is expected to rise with aging. Cholesterol lowering drugs occupy vital part in the management of cardiovascular events in patients.
The prevalence of LDL cholesterol in patient population has also been a steady factor.
On the regional front, Asia Pacific is brimming with massive opportunities. This is due to the presence of vast patient pool. Further, the growing awareness of mortality arising out of bad cholesterol in the regional populations also bolster the prospects of cholesterol-lowering drugs. People with lifestyle-driven heart diseases has also risen, boosting the awareness. Further, rapidly aging populations in some of the countries also will contribute revenue stream to numerous global drug manufacturers.
Analyze cholesterol lowering drugs market growth in 30+ countries including US, Canada, Germany, United Kingdom, ASEAN Countries, Japan, India, China, and Japan. Request a sample of the study.
Players in the cholesterol lowering drugs market are striving to develop alternatives to statins. Manufacturers are bolstering production capabilities to and harnessing the potential in bempedoic acid to unveil better drug formulations. Top players are leaning on obtaining approvals for bempedoic-induced drugs in Europe. In coming years, they will be focusing on unveiling oral cholesterol lowering drugs with better tolerability.
Some of the drug companies looking to strengthen their stakes in the cholesterol lowering drugs market are Amgen Inc., Merck & Co., Inc., Novartis AG, GlaxoSmithKline plc, and Sanofi. These players are leaning on research and development of drugs approvals that can target specific indications. To this end, they are entering into partnerships and deals.
The cholesterol lowering drugs market is segmented on the basis of:
Cholesterol Lowering Drugs Market, by Drug Class
Statins & Combination
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Cholesterol Lowering Drugs Market, by Indication
Coronary Artery Disease
Cholesterol Lowering Drugs Market, by Distribution Channel
Cholesterol Lowering Drugs Market, by Region
Rest of Europe
Australia & New Zealand
Rest of Asia Pacific
Rest of Latin America
Middle East & Africa
Rest of Middle East & Africa
Explore Transparency Market Research's award-winning coverage of the global Healthcare industry:
Precision Medicine Market - The standard solutions open in the market, routinely present the limitation of a 'one-size fits-all' approach, which may not be sensible for every individual in light of innate differences. Precision medicine is a reaction to this control. Exactness prescription is an absolutely new thought and development which has been getting vitality in the past scarcely any years, and in this way, has become a promising zone for business adventure for critical pharmaceutical associations. The interest for new medications for different illnesses is the explanation that the worldwide precision medicine market is developing quickly in the term of 2016 to 2024.
Atherosclerosis Drugs Market - Despite the prevalence of diabetes and cholesterol among a wide patient pool, the atherosclerosis drugs market will move at a sluggish CAGR of 2.5% during the forecast period, finds a recently published report by Transparency Market Research (TMR).
Coronary Artery Disease Therapeutics Market - The global coronary artery disease therapeutics market is anticipate to expand in the near future. This is because of a surge in the demand of these therapeutics owing to the rising incidences of chronic disease across the globe. Coronary Artery Disease Therapeutics is procedure which include several techniques such as stem cells, nanotechnology and robotic surgery for the efficient treatment of Coronary Artery Disease.
Gain access to Market Ngage, an AI-powered, real-time business intelligence that goes beyond the archaic research solutions to solve the complex strategy challenges that organizations face today. With over 15,000+ global and country-wise reports across 50,000+ application areas, Market Ngage is your tool for research on-the-go. From tracking new investment avenues to keeping a track of your competitor's moves, Market Ngage provides you with all the essential information to up your strategic game. Power your business with Market Ngage's actionable insights and remove the guesswork in making colossal decisions.
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision."